Clinical trials: Recurrent Tumor
Multiple Myeloma, Relapsed Cancer
A Study of ANV419 Alone or in Combination With Approved Treatments in Patients With Multiple Myeloma (OMNIA-2)
The purpose of this study is to evaluate the safety and tolerability of ANV419 monotherapy followed by ANV419 in combination with lenalidomide plus low-dose dexamethasone or ANV419 in combination with daratumumab.
- Conditions
- Multiple Myeloma, Relapsed Cancer, Refractory Multiple Myeloma, Adult Disease
- Trial name
- NCT05641324
- Testing
- ANV419, Lenalidomide with low-dose dexamethasone, Daratumumab
- Where
- 11 sites in Denmark, France and 3 more
- Volunteers
- 4 people
- Sponsor
- Anaveon AG
Pain, Prostate Cancer
Combination Chemotherapy in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving more than one drug may kill more tumor cells.
- Trial name
- NCT00005960
- Testing
- filgrastim, cyclophosphamide, docetaxel
- Where
- 6 sites in United States
- Sponsor
- Amgen
HPV Positive Oropharyngeal Squamous Cell Carcinoma, HNSCC
Safety and Efficacy of VB10.16 and Pembrolizumab in Patients With Head-Neck Squamous Cell Carcinoma
This is a multi-center study in patients with un-resectable Recurrent or Metastatic HPV16-positive oropharyngeal Head and Neck Squamous Cell Carcinoma (HNSCC).
- Trial name
- NCT06016920
- Testing
- VB10.16, Pembrolizumab
- Where
- 12 sites in France, Germany and 5 more
- Volunteers
- 110 people
- Sponsor
- Nykode Therapeutics ASA
Recurrent Genital Herpes
Efficacy and Safety of Oral Famciclovir in Patients With Active Recurrent Genital Herpes
This is a phase III, multicenter, randomized, double-blind, parallel-group study to compare the efficacy and safety of a two-day treatment with famciclovir (500 mg loading dose followed by 250 mg 12-hourly) to standard five-day…
- Trial name
- NCT00171990
- Testing
- Famciclovir
- Where
- Australia
- Volunteers
- 1,461 people
- Sponsor
- Novartis
Non-Hodgkin's Lymphoma, Lymphoma, B-Cell
Treatment of Non-Hodgkin's Lymphoma With 90Y-hLL2 IgG
The purpose of this trial is to determine the safety of a 90Y-radiolabeled, humanized (CDR-grafted) form of the LL2 monoclonal antibody in patients with Non-Hodgkin's lymphoma (NHL) at different dose levels.
- Trial name
- NCT00061425
- Testing
- radiolabeled epratuzumab
- Sponsor
- Gilead Sciences
Multiple Myeloma, NonHodgkin Lymphoma
A Dose Finding Study Followed by a Safety and Efficacy Study for Patients With Multiple Myeloma or Lymphoma
The Phase 1 portion of this study will determine the safety of TAS4464 and the most appropriate dose for patients with Multiple Myeloma or Lymphoma.
- Trial name
- NCT02978235
- Testing
- TAS4464
- Where
- 7 sites in United States
- Volunteers
- 11 people
- Sponsor
- Taiho Oncology, Inc.
Leukemia, Myeloid, Acute, Refractory AML
Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia
The main purpose of this study is to identify a safe and potentially effective dose of tuspetinib to be used in future studies in study participants diagnosed with acute myeloid leukemia (AML), myelodysplastic syndromes with…
- Conditions
- Leukemia, Myeloid, Acute, Refractory AML, Relapsed Adult AML, Myelodysplastic Syndrome With Excess Blasts-2
- Trial name
- TUSCANY (NCT03850574)
- Testing
- Tuspetinib, Venetoclax Oral Tablet, Azacitidine for Intravenous Infusion
- Where
- 34 sites in United States, Australia and 4 more
- Volunteers
- 240 people
- Sponsor
- Aptose Biosciences Inc.
Relapsed/Refractory, High Risk Hematologic Malignancies, T-ALL/Lymphoma
CD7 CAR-T Cell Treatment of Relapsed/Refractory CD7+ T -Acute Lymphoblastic Leukemia/ Lymphoma
This is a phase I, interventional, single arm, open label, treatment study to evaluate the safety and tolerability of CD7 CAR-T cells in patients with relapsed and/or refractory, high risk hematologic malignancies.
- Trial name
- NCT05212584
- Testing
- CD7CAR T cells
- Where
- China
- Volunteers
- 24 people
- Sponsor
- iCell Gene Therapeutics
Leukemia, Myelodysplastic Syndromes
Study of Gene Modified Donor T Cell Infusion in Patients With Recurrent Disease After Allogeneic Transplant
A Phase I study of BPX-501 T cell infusion in adults with recurrent or minimal residual disease (MRD) hematologic malignancies post-allogeneic transplant.
- Conditions
- Leukemia, Myelodysplastic Syndromes, Lymphoma, Multiple Myeloma
- Trial name
- NCT02477878
- Testing
- BPX-501, Rimiducid
- Where
- 5 sites in United States
- Volunteers
- 10 people
- Sponsor
- Bellicum Pharmaceuticals
Ovarian Cancer
Study of XL999 in Patients With Previously Treated Ovarian Cancer
This clinical trial is being conducted at multiple sites to evaluate the activity, safety, and tolerability of XL999 when given weekly to patients with ovarian cancer that has previously been treated with platinum-based…
- Trial name
- NCT00277290
- Testing
- XL999
- Where
- 9 sites in United States
- Volunteers
- 24 people
- Sponsor
- Symphony Evolution, Inc.
Herpes Simplex Type 2
Biological Efficacy Study of HerpV Vaccine With QS-21 to Treat Participants With Recurrent Genital Herpes
The purpose of this study is to evaluate the effect of recombinant human heat shock protein 70-polyvalent peptide complex (HerpV) vaccine administration on recurring episodes of genital herpes by evaluating viral shedding before…
- Trial name
- NCT01687595
- Testing
- HerpV and QS-21
- Where
- 5 sites in United States
- Volunteers
- 80 people
- Sponsor
- Agenus Inc.
Lung Cancer
DX-8951f in Treating Previously Untreated Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of DX-8951f in treating patients who have previously…
- Trial name
- NCT00005091
- Testing
- exatecan mesylate
- Where
- 6 sites in Finland, Germany and 3 more
- Sponsor
- Daiichi Pharmaceuticals
Recurrent or Metastatic Nasopharyngeal Carcinoma
A Study of MRG003 in Combination With Pucotenlimab Versus Chemotherapy in the Treatment of Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma
This is a randomized, open-label, multi-center, phase III study to evaluate the efficacy and safety, and immunogenicity of MRG003 in combination with pucotenlimab in patients with recurrent or metastatic nasopharyngeal carcinoma.
- Trial name
- Magic-C002 (NCT06976190)
- Testing
- MRG003 + Pucotenlimab, Gemcitabine, Docetaxel, or Capecitabine
- Where
- China
- Volunteers
- 446 people
- Sponsor
- Lepu Biopharma Co., Ltd.
Neoplasms
A Study of BXQ-350 in Children and Young Adults With Relapsed Solid Tumors
This study will evaluate the safety of BXQ-350 and determine the maximum tolerated dose (MTD) in children and young adults with relapsed solid tumors, including recurrent malignant brain tumors.
- Trial name
- KOURAGE (NCT03967093)
- Testing
- BXQ-350
- Where
- 2 sites in United States
- Volunteers
- 9 people
- Sponsor
- Bexion Pharmaceuticals, Inc.
Renal Cell Carcinoma Recurrent
Study of the Combination of CM082 With Everolimus in Patients With mRCC
This is a Phase I Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of CM082 in Combination with Everolimus in Chinese Patients With Advanced Renal Cell Carcinoma.
- Trial name
- NCT02577458
- Testing
- CM082, Everolimus
- Where
- China
- Volunteers
- 18 people
- Sponsor
- AnewPharma
Breast Cancer
Lynparza Breast Cancer Clinical Experience Investigation
To characterise the development of ADRs of bone marrow depression in patients under actual post-marketing use
- Trial name
- NCT03590938
- Where
- 31 sites in Japan
- Volunteers
- 111 people
- Sponsor
- AstraZeneca
Prostate Cancer, Neoplasm Metastasis
BAY88-8223, Dose Finding Study in Patients With HRPC
The purpose of this study is to evaluate the effectiveness of the investigational radioisotope Radium-223, Alpharadin, in treatment of men with prostate cancer and bone metastases that no longer respond to hormonal treatment.
- Trial name
- NCT00337155
- Testing
- Radium-223 dichloride (BAY88-8223)
- Where
- United Kingdom
- Volunteers
- 122 people
- Sponsor
- Bayer
Ovarian Cancer
Efficacy of NOV-002 in Combination With Carboplatin in Chemotherapy-resistant Ovarian Cancer
The purpose of this trial is to determine the tumor response rate of NOV-002 plus carboplatin in a cohort of women with platinum resistant cancer of ovarian origin.
- Trial name
- NCT00345540
- Testing
- NOV-002, Carboplatin
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- Cellectar Biosciences, Inc.
Triple-Negative Breast Cancer (TNBC)
A Study of MR001 in Patients With Locally Recurrent or Metastatic Advanced Triple-Negative Breast Cancer (TNBC)
This Phase Ib/IIa study is evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of MR001 in patients with advanced triple-negative breast cancer (TNBC) who have progressed after prior therapy.
- Trial name
- NCT07208149
- Testing
- MR001 Bispecific Antibody for Injection
- Where
- China
- Volunteers
- 42 people
- Sponsor
- Shenzhen Majory Biotechnology Co., Ltd.
Diffuse Large B-cell Lymphoma (DLBCL)
Study of Efficacy and Safety of CTL019 in Adult DLBCL Patients
This is a multi-center, phase II study to determine the efficacy and safety of CTL019 in adult patients with relapsed or refractory DLBCL.
- Trial name
- JULIET (NCT02445248)
- Testing
- Tisagenlecleucel, Lymphodepleting chemotherapy
- Where
- 26 sites in United States, Australia and 8 more
- Volunteers
- 115 people
- Sponsor
- Novartis Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.